Clinical Trial Update: Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating the efficacy and safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de novo kidney transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Enteric-coated Mycophenolate Sodium (EC-MPS) (mycophenolate sodium)

Snippet

Sponsor: Novartis | Conditions: Renal Transplantation | Phase 4 | Status: COMPLETED